SL1002
Phase 3Small molecule
SL1002 is one of 27 small molecule programs targeting Osteoarthritis. It is currently in Phase 3.
2
Indications
1
Total Trials
1
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
778 competitors in Osteoarthritis
#DrugCompanyPhaseTrials
1SL1002
SSaol Therapeutics Inc
Phase 3
Ilaris
NovartisPreclinical
Toradol
RochePreclinical
Voltaren
CCerimon Pharmaceuticals
Preclinical
Platelet Rich Plasma
ZZagazig University
Preclinical
Enbrel
IImmunex
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Protonix
WWyeth-Lederle Vaccines
Preclinical
Paracetamol
GSKPreclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SL1002. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SSaol Therapeutics Inc